Turning Point Therapeutics (TPTX) stock forecast for 2024
Last update: 05-19-2022, 12:32
Sector: HealthcareThe share price of Turning Point Therapeutics, Inc. (TPTX) now
What analysts predict:: $104.56
52-week high/low: $83.06 / $23.77
50/200 Day Moving Average: $29.07 / $44.68
This figure corresponds to the average price over the previous 50/200 days. For Turning Point Therapeutics stocks, the 50-day moving average is the support level today.
For Turning Point Therapeutics stocks, the 200-day moving average is the resistance level today.
Are you interested in Turning Point Therapeutics stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Turning Point Therapeutics stock price in 2024. How much will one Turning Point Therapeutics share be worth in 2024?
Is it worth taking profit / loss on Turning Point Therapeutics stock now or waiting? What are analysts' forecasts for Turning Point Therapeutics stock?
We forecast Turning Point Therapeutics stock performance using neural networks based on historical data on Turning Point Therapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
The Turning Point Therapeutics stock prediction results are shown below and presented as a graph, table and text information.
Turning Point Therapeutics stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Turning Point Therapeutics analysts is $104.56.
Today 200 Day Moving Average is the resistance level (44.68 $).
50 Day Moving Average is the support level (29.07 $).
Historical and forecast chart of Turning Point Therapeutics stock
The chart below shows the historical price of Turning Point Therapeutics stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Turning Point Therapeutics stock price can be found in the table below.
Turning Point Therapeutics (TPTX) Forecast for 2024
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 38.05 | 31.52 | 43.82 | 28.08 % |
| Feb | 31.77 | 29.67 | 37.22 | 20.28 % |
| Mar | 28.48 | 25.79 | 29.86 | 13.64 % |
| Apr | 22.34 | 19.15 | 23.82 | 19.61 % |
| May | 20.67 | 19.08 | 23.31 | 18.14 % |
| Jun | 18.90 | 16.15 | 20.69 | 21.91 % |
| Jul | 23.01 | 20.69 | 25.39 | 18.54 % |
| Aug | 26.71 | 23.01 | 30.47 | 24.49 % |
| Sep | 22.48 | 20.65 | 26.44 | 21.89 % |
| Oct | 22.43 | 19.96 | 26.13 | 23.61 % |
| Nov | 21.79 | 18.48 | 23.08 | 19.94 % |
| Dec | 22.36 | 19.02 | 24.33 | 21.84 % |
Turning Point Therapeutics information and performance
Turning Point Therapeutics, Inc., a clinical stage biopharmaceutical company, designs and develops new small molecule targeted cancer therapies. He is developing a suite of tyrosine kinase inhibitors (TKIs) that targets cancer genetic factors in previously TKI-naive and TKI-treated patients.
Turning Point Therapeutics Address
10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, US
Market Capitalization: 1 792 457 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: -46 895 000 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: None
Price/earnings to growth
DPS: N/A
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
DY: N/A
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS: -4.802
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: -0.982
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: -
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 106.25
Enterprise Value (EV) /Revenue
EV To EBITDA: -
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 49666300
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Turning Point Therapeutics price target for 2021 by month
Target values for the price of one Turning Point Therapeutics share for Jan 2024.
Pessimistic target level: 31.52
Optimistic target level: 43.82
Target values for the price of one Turning Point Therapeutics share for Feb 2024.
Pessimistic target level: 29.67
Optimistic target level: 37.22
Target values for the price of one Turning Point Therapeutics share for Mar 2024.
Pessimistic target level: 25.79
Optimistic target level: 29.86
Target values for the price of one Turning Point Therapeutics share for Apr 2024.
Pessimistic target level: 19.15
Optimistic target level: 23.82
Target values for the price of one Turning Point Therapeutics share for May 2024.
Pessimistic target level: 19.08
Optimistic target level: 23.31
Target values for the price of one Turning Point Therapeutics share for Jun 2024.
Pessimistic target level: 16.15
Optimistic target level: 20.69
Target values for the price of one Turning Point Therapeutics share for Jul 2024.
Pessimistic target level: 20.69
Optimistic target level: 25.39
Target values for the price of one Turning Point Therapeutics share for Aug 2024.
Pessimistic target level: 23.01
Optimistic target level: 30.47
Target values for the price of one Turning Point Therapeutics share for Sep 2024.
Pessimistic target level: 20.65
Optimistic target level: 26.44
Target values for the price of one Turning Point Therapeutics share for Oct 2024.
Pessimistic target level: 19.96
Optimistic target level: 26.13
Target values for the price of one Turning Point Therapeutics share for Nov 2024.
Pessimistic target level: 18.48
Optimistic target level: 23.08
Target values for the price of one Turning Point Therapeutics share for Dec 2024.
Pessimistic target level: 19.02
Optimistic target level: 24.33